文献速递淋巴瘤

复发/难治性大B细胞淋巴瘤患者接受阿基仑赛前的桥接治疗

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

本研究评估了148例计划接受阿基仑赛输注的大B细胞淋巴瘤患者在白细胞分离术后接受桥接治疗(BT)的影响。55%(n=81)接受BT的患者更可能有IPI评分≥3、大包块疾病和LDH升高。未接受BT患者1年PFS和OS分别为40%和65%,BT患者分别为21%和48%(P=.01和.05)。在124例接受阿基仑赛的患者中,BT与非BT队列的1年PFS和OS无显著差异。

要点

  • 需要桥接治疗的患者预后较差,1年PFS 21% vs 40%,1年OS 48% vs 65%。
  • 在124例接受阿基仑赛的患者中,BT与非BT的1年PFS和OS无显著差异(P=.06和.21)。
  • 与未桥接患者相比,全身治疗桥接患者1年PFS更差(P=.01);放疗桥接患者PFS优于全身治疗桥接患者(P=.05)。

核心结论

  • 尽管需要桥接治疗与不良预后相关,放疗可以是一种有效的桥接策略。
  • 未来需要研究来确定可能改善CAR T细胞治疗可及性和结局的策略。

研究设计与样本

  • 评估148例为大B细胞淋巴瘤计划接受阿基仑赛输注而进行白细胞分离术的患者中,桥接治疗(全身治疗、放疗或联合模式治疗)对结局的影响。

主要发现

  • 55%(n=81)的患者接受了桥接治疗,更可能有国际预后指数评分≥3(P≤.01)、大包块疾病(P=.01)和乳酸脱氢酶升高(P≤.01)。
  • 未接受桥接治疗患者1年无进展生存率和总生存率分别为40%和65%,接受桥接治疗患者分别为21%和48%(P=.01和.05)。
  • 24例患者(16%)未接受阿基仑赛,最常见原因是淋巴瘤进展(88%),尽管80%(n=19)接受了桥接治疗。
  • 在124例接受阿基仑赛的患者中,50%(n=62)接受了桥接治疗,其中全身治疗45例、放疗11例、联合模式治疗6例;桥接与非桥接队列的1年无进展生存率和总生存率无显著差异(P=.06和.21)。
  • 全身治疗、放疗和联合模式治疗组之间,国际预后指数≥3、局限期疾病或乳酸脱氢酶升高的患者比例无差异;与未桥接患者相比,全身治疗桥接患者1年无进展生存率更差(P=.01);放疗桥接患者无进展生存率优于全身治疗桥接患者(P=.05)。

局限性

  • 未来需要研究来确定可能改善CAR T细胞治疗可及性和结局的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease (P = .01), and elevated lactate dehydrogenase (LDH; P ≤ .01). The 1-year progression-free (PFS) and overall survival (OS) rates were 40% and 65% in non-BT patients vs 21% and 48% in BT patients (P = .01 and .05, respectively). Twenty-four patients (16%) did not receive axi-cel, most commonly because of lymphoma progression (88%), despite 80% (n = 19) receiving BT. Among 124 patients who received axi-cel, 50% (n = 62) received BT with ST (n = 45), RT (n = 11), or CMT (n = 6); 1-year PFS and OS rates were not significantly different between BT and non-BT cohorts (P = .06 and .21, respectively). There was no difference in proportion of patients with IPI ≥3, limited-stage disease, or elevated LDH between ST, RT, and CMT groups. Compared with non-BT patients, 1-year PFS was inferior for ST-bridged patients (P = .01). RT-bridged patients had improved PFS compared with ST-bridged patients (P = .05). Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy. Future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020. PMID: 32589728. doi:10.1182/bloodadvances.2020001837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。